[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614390":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":44,"responsibleParty":130,"collaborators":24,"id":133,"slug":134,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":135,"sex":141,"minAge":142,"maxAge":24,"enrollmentInfo":143,"targetDuration":24,"studyType":146,"phases":147,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":46,"whyStopped":24,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"AUB Santé","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence 1: HD HDF","EXPERIMENTAL","The patient will receive three months of HD followed by three months of HDF",[13,14],"Other: High-flux hemodialysis","Other: Hemodiafiltration",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence 2: HDF HD","The patient will receive three months of HDF followed by three months of HD",[13,14],[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"High-flux hemodialysis","High-flux hemodialysis removes small and middle molecular solutes through the mechanism of diffusion.",[9,16],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Hemodiafiltration","Hemodiafiltration removes solutes using convection which allows for more epuration of middle molecular solutes.",[9,16],[30],{"name":31,"affiliation":32,"role":33},"Mabel Aoun, M.D., M.P.H.","AUB SANTE","STUDY_CHAIR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":24,"email":39},"Mabel AOUN, M.D., M.P.H.","CONTACT","+33174743551","aounmabel@yahoo.fr",{"name":41,"role":37,"phone":42,"phoneExt":24,"email":43},"Sibylle Gourvil","02.90.22.64.05","sibylle.gourvil@aub-sante.fr",[45,73,90,111],{"facility":5,"status":46,"city":47,"state":24,"zip":24,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Bretagne","France","FR",{"type":51,"coordinates":52},"Point",[53,54],6.9977,47.59535,{"lat":54,"lon":53},[57,61,64,66,69,71],{"name":58,"role":37,"phone":59,"phoneExt":24,"email":60},"Thibault DOLLEY-HITZE, M.D.","+33299200140","thibault.dolley-hitze@aub-sante.fr",{"name":62,"role":37,"phone":24,"phoneExt":24,"email":63},"Simon DUQUENNOY, M.D.","simon.duquennoy@aub-sante.fr",{"name":58,"role":65,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"name":67,"role":68,"phone":24,"phoneExt":24,"email":24},"Eric LARUELLE, M.D.","SUB_INVESTIGATOR",{"name":70,"role":68,"phone":24,"phoneExt":24,"email":24},"Morgane GOSSELIN, M.D.",{"name":72,"role":68,"phone":24,"phoneExt":24,"email":24},"Bruno LEGENDRE, M.D.",{"facility":74,"status":46,"city":75,"state":24,"zip":76,"country":48,"countryCode":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"AIDER","Grabels","34790",{"type":51,"coordinates":78},[79,80],3.80144,43.648,{"lat":80,"lon":79},[83,86,89],{"name":84,"role":37,"phone":24,"phoneExt":24,"email":85},"Annie RODRIGUEZ","a.rodriguez@aidersante.com",{"name":87,"role":37,"phone":24,"phoneExt":24,"email":88},"Anne WUILLAI, M.D.","a.wuillai@aidersante.com",{"name":87,"role":65,"phone":24,"phoneExt":24,"email":24},{"facility":91,"status":46,"city":92,"state":24,"zip":24,"country":48,"countryCode":49,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"ECHO","Le Mans",{"type":51,"coordinates":94},[95,96],0.20251,48.0021,{"lat":96,"lon":95},[99,103,105,106,107,109],{"name":100,"role":37,"phone":101,"phoneExt":24,"email":102},"Guillaume SERET, M.D.","+33243432474","gseret@echo-sante.com",{"name":104,"role":37,"phone":24,"phoneExt":24,"email":24},"Frédéric LAVAINNE, M.D.",{"name":100,"role":65,"phone":24,"phoneExt":24,"email":24},{"name":104,"role":68,"phone":24,"phoneExt":24,"email":24},{"name":108,"role":68,"phone":24,"phoneExt":24,"email":24},"Lurlings GENDROT, M.D.",{"name":110,"role":68,"phone":24,"phoneExt":24,"email":24},"Wael AL HAGGAN, M.D.",{"facility":112,"status":46,"city":113,"state":24,"zip":24,"country":48,"countryCode":49,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Aura Paris","Paris",{"type":51,"coordinates":115},[116,117],2.3488,48.85341,{"lat":117,"lon":116},[120,124,126,127,128],{"name":121,"role":37,"phone":122,"phoneExt":24,"email":123},"Pablo URENA, M.D.","+33149189393","pablo.urena@auraparis.org",{"name":125,"role":37,"phone":24,"phoneExt":24,"email":24},"Rime OSSMANE, M.D.",{"name":121,"role":65,"phone":24,"phoneExt":24,"email":24},{"name":125,"role":68,"phone":24,"phoneExt":24,"email":24},{"name":129,"role":68,"phone":24,"phoneExt":24,"email":24},"Minh Hoang TRAN, M.D.",{"type":65,"investigatorFullName":131,"investigatorTitle":132,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Mabel Aoun","Nephrologist","100614390","hemodiafiltration-versus-hemodialysis-in-older-people-100614390",false,"NCT07278973","Hemodiafiltration Versus Hemodialysis in Older People","HemoDiafiltration Versus HemoDialysis in OLDER People: a Randomized, Multicenter, Crossover, Pragmatic Clinical Trial","HD-OLDER","Inclusion Criteria:\n\n* Signed and dated informed consent\n* Age \\>84 years\n* Diagnosed with kidney failure\n* On maintenance hemodialysis \\>3months\n* Willing to have a dialysis session of 3.5 to 4-hour duration, three times a week\n* Has a reliable vascular access\n* Is covered by the health insurance\n\nExclusion Criteria:\n\n* Patients with cognitive impairment (assessed with a mini-test if needed)\n* Hospitalized at inclusion\n* Have difficulties with French speaking\n* Terminally ill with life expectancy\\\u003C3 months\n* With active cancer","ALL","85 Years",{"count":144,"type":145},62,"ESTIMATED","INTERVENTIONAL",[148],"NA","This study will compare the impact of two hemodialysis techniques on fatigue and post-dialysis recovery time in patients aged 85 years and older. These two techniques are high-flux hemodialysis (HD) and hemodiafiltration (HDF).\n\nPatients will receive the treatment over two periods: if period 1 is HD then period 2 will be HDF. Every patient will be his\u002Fher own control, this is why it is called cross-over. Each period will last three months. Between the two periods, patients will receive a traditional low-flux hemodialysis.\n\nThese two techniques are widely used worldwide and their side-effects are well-known and do not put the patients at risk. HDF has been shown to improve survival in patients with a mean age of 58 years. But a previous study from the investigators' group showed that HDF causes a prolonged recovery time in older patients. This randomized trial aims to elucidate this question.",[151,26,152,153,154],"Hemodialysis","Fatigue Symptom","Quality of Life of Patients","Older People",[151,26,156,157,158,159],"Older people","Fatigue","Patient reported outcome","Dialysis recovery time","2026-02-20",{"date":162,"type":163},"2026-02-23","ACTUAL",{"date":165,"type":145},"2026-02-19",{"date":167,"type":145},"2026-12-19",{"name":5,"class":6},4]